

LE Magazine September 2004

REPORT

An Innovative New Treatment for Migraine

By Dr. Sergey A. Dzugan



The following article details a groundbreaking treatment program that achieved a 100% success rate for the cessation of migraine headaches during the study period. The cause and relief of migraine is an extremely complex issue involving hormonal balance, neurochemicals, and metabolic integrity. While this article may appear somewhat complicated, it summarizes years of research that can now deliver relief from migraine. If you or someone you know suffers from migraine, we encourage you to read the following article very carefully and to share it with your physician.

While recent advances in treatment have reduced the symptoms of suffering for millions of migraine patients, the underlying causes of migraine continue to be a focus of debate. In this article, we will present an innovative treatment that cured all patients treated for migraine in a recent study. This study was initially conducted at the North Central Mississippi Regional Cancer Center in

Greenwood, MS, in association with Dr. Arnold Smith, and was continued at the Life Extension Foundation.

The Continuing Mystery of Migraine

The history of the treatment of headaches in general, and migraine in particular, predates the current millennium. Around 1500 BC, the Pharaoh's courts of ancient Egypt provided the first descriptions of unilateral headaches accompanied by vomiting and malaise. Of all medical disorders, migraine has one of the longest histories of recognition without sufficient understanding. Beset by myths, uncertain etiology, and inadequate treatment, migraine remains one of the most undertreated neurological conditions today. It seems frustrating that despite the long history of migraine, treatment for this ancient complaint, irrational at times and empirical at others, has evolved slowly and tortuously, yet is still without a universal standard.¹

Migraine affects about 10-15% of the population in various countries.²⁻⁴ Migraine may occur at any age, but its prevalence increases from childhood up to 40 years of age.⁵ Migraine is more common in women than in men. According to the American Migraine Study, 17.6% of females and 6% of males in the US currently suffer from severe migraine.⁶

The numerous theories and hypotheses that have been advanced concerning the causes of migraine are a subject of dispute among experts on the disorder.⁷ For example, the theory of migraine as a result of dilated blood vessels in the brain was suggested in the early 1850s by Brown-Sequard and Claude Bernard. Their theory was rebutted, however, when Du Bois-Reymond proposed constriction of the brain's blood vessels as the cause of migraine in 1860.⁸

Today, no single hypothesis readily explains the mechanism underlying migraine.⁹ Because of this, new hypotheses continue to emerge but defy acceptance,¹⁰ as shown in the accompanying sidebar. While sufficient scientific data exist to support many disparate hypotheses, scientists have yet to promulgate a single hypothesis that explains all the laboratory findings and clinical observations.

Current Treatment Approaches

From a traditional standpoint, migraine appears to be a primary disorder of the cerebral vessels.²⁷ Current treatments for migraine includes dietary changes, stress management, proper sleep, hormone replacement therapy, supplements, and prescription drugs.

As one might expect, each hypothesis is accompanied by its own recommended treatment regimen and no single treatment is effective for everyone, or even for a given person with every migrainous attack.

POPULAR THEORIES TO EXPLAIN MIGRAINE

- Inadequate regulation by the autonomic nervous system^{11,12}
- Faulty interaction between the autonomic nervous system and hormones¹³
- Serotonin effect¹⁴
- Prostaglandin effect^{15,16}
- Platelet abnormality¹⁷⁻¹⁹
- Reaction to decreased oxygen in the blood and tissues²⁰
- Vasospasm^{21,22}
- Muscle hypercontractility²³
- Genetic predisposition²⁴
- Neural hyperexcitability²⁵
- Disruption of normal pain pathways²⁶

As a result, it is not surprising that so many migraine sufferers (migraineurs) express dissatisfaction with their treatment and discontinue treatment despite continued debilitating migraine. Indeed, 44.5% of patients surveyed reported adverse events after using various drugs for migraine, and these side effects were considered serious in 1.7% of those treated.²⁸ The adverse events, including dizziness, nausea, headache, tingling of the fingers or toes, difficulty in thinking, and fatigue, are evidence of the need for safer, more effective medications for the treatment of migraine.^{29,30} While behavioral management and relaxation training are important complements to pharmacological therapy, drugs remain the mainstay of migraine therapy.³¹⁻³⁷

In reviewing the medical literature in an effort to determine the cause of migraine, one repeatedly encounters several consistently documented abnormalities:

1. widespread derangement of serotonin metabolism and excessive release of neurotransmitters;³⁸
2. hyperexcitability of the brain as a result of low intracellular magnesium levels or increased neurotoxic amino acids; and
3. hormonal imbalance.

DRUGS USED TO TREAT MIGRAINE

- Anti-nausea drugs
- Anti-anxiety drugs
- Anti-inflammatories
- Ergot
- Steroids
- Tranquilizers
- Narcotic pain relievers
- Serotonin promoters

DRUGS USED TO PREVENT MIGRAINE

- Beta-blockers
- Calcium channel blockers
- Antidepressants
- Serotonin blockers
- Anticonvulsants

Several studies performed since the 1960s have demonstrated that migraine is caused by a primary biochemical disorder of the central nervous system involving neurotransmitters, and serotonin in particular. Serotonin has long been implicated as a key neurotransmitter in migraine.³⁹ The body's serotonin level falls during a migraine attack.⁴⁰ Among its other actions, the release of serotonin results in blood vessel constriction in the brain and impaired neural transmission.

The pineal gland, a primary source of serotonin and melatonin, is also known to contribute significantly to migraine attacks.^{41,42} Research has found that the pineal hormone melatonin is low in migraine patients,⁴³ suggesting impaired pineal function.⁴⁴ Additionally, several studies have demonstrated that the administration of melatonin to migraine sufferers relieved pain and decreased headache recurrence in some cases.^{43,45} It has been suggested that the pineal gland could act as the intermediate causative factor of migraine, via a derangement of melatonin.⁴² The melatonin precursor serotonin showed diurnal variations with opposite phases to melatonin synthesis.⁴⁶ What this indicates is that serotonin levels rise during the daytime and fall at night. Melatonin levels rise at night and decrease during the day. Stress and dietary habits lead to deficiencies of both serotonin and melatonin. A diminished ratio of melatonin to serotonin leads to a decline in adaptive processes.⁴⁷ Also, abnormal circadian rhythms of cortisol may occur in states of decreased melatonin.⁴⁸ Our research supports the hypothesis that migraine is a response to a pineal circadian irregularity, and that the administration of melatonin normalizes this circadian cycle;⁴⁵ that is, melatonin may play a role in resynchronizing biological rhythm to lifestyle, and may subsequently relieve migraine.

During the last 15 years, many researchers have proposed that migraine is generated by a hyperexcitable brain. A migraine attack can be triggered at any time, depending on the threshold of brain excitability, and in fact, the frequency of migraines is proportional to the excitability level. According to classic theory, a migraine attack is initiated by a cerebrovascular spasm followed by extracranial vasodilatation. This change may be caused by an imbalance in brain biochemistry. Decreased cellular oxygen can cause an increase in the flow of calcium from the extracellular fluid to the intracellular space, resulting in a calcium overload and cellular dysfunction.⁴⁹ Disturbances in mitochondrial oxidation reactions, magnesium deficiency, or abnormalities of cellular calcium channels may be responsible for the neuronal hyperexcitability between attacks.⁵⁰ We believe that the restoration of calcium-magnesium balance is one of the critical issues in migraine therapy.

REPORT

An Innovative New Treatment for Migraine

By Dr. Sergey A. Dzugan

Sex Hormones and Headaches

Migraine affects approximately three times as many women as men, suggesting that gonadal steroids may play a role. Furthermore, headaches have been linked to menstrual cyclicity. Migraine attacks occur during menses in 60% of women. Changes in estrogens levels at menarche and during menstruation, pregnancy, and menopause may trigger migraine. Indeed, the physiological decline in estrogens levels that occurs with menstruation, or a therapeutic withdrawal as occurs during hormonal blocking therapy, often precipitates migraine, whereas the sustained high estrogens levels that occur during pregnancy frequently result in relief from headaches.^{51,52}



In some cases, estrogens replacement therapy for menopausal symptoms induces headache. The incidence and severity of migraine are also affected by use of oral contraceptives.⁵³ In migrainous women, 17-beta-estradiol levels are higher in both the follicular (before release of an egg) and luteal (after release of an egg) phases of the menstrual cycle, whereas progesterone concentrations and the ratio of progesterone to estradiol are lower than in healthy subjects during the luteal phase of the menstrual cycle.⁵⁴ Menstrual distress was highest during the luteal and menstrual phases of the cycle, and these symptoms were related to higher estradiol levels, higher ratios of estradiol to progesterone, and increased headache activity.⁵⁵



Because of these controversies, we maintain that the main problem is an imbalance between estrogens and progesterone levels rather than the absolute levels of these hormones. This can explain, for example, why migraine was relieved by using Zoladex®, which blocks estrogen release from the ovary and improves the ratio of estrogens to progesterone.⁵⁶ Menstrual migraine therefore represents a model that coincides with a neuroendocrine hypothesis.¹³ Effects of hormonal imbalances and deficiencies on vasomotor control are clinically significant, and hormonal treatment is often effective in managing various conditions caused by abnormal blood flow, including migraine.⁵⁷

In this way, estrogens are known to exert their influence by modulating sympathetic control of cerebral vasculature.¹² Not surprisingly, various trials have been conducted using estrogens, progestogens, and dehydroepiandrosterone (DHEA) to manage migraine; the findings from these trials, however, have been inconsistent.⁵⁸⁻⁶⁰ Despite copious research, the proper therapeutic use of hormones remains in question.^{61,62}

The fluctuations in estrogens levels associated with migraine also produce biochemical changes in prostaglandin production, prolactin release, and endogenous opioid regulation. Prostaglandin E2 (PGE-2) is a well-defined mediator of fever and inflammation. PGE-2 increases vasodilatation and thereby induces pain. Estrogens increase the production of PGE-2. An excess of estrogens, deficit of progesterone, or dominance of estrogens can cause increased production of PGE-2, resulting in migraine. Elevation of the prolactin level or increased sensitivity to prolactin leads to a decreased level of prostaglandin E1 (PGE-1). Patients with migraine may have prostaglandin-induced hyper-sensitivity to prolactin. PGE-1 is a substance that in fact improves the microcirculation and leads to the development of collateral circuits with a consequent improvement in local hemodynamics. If the patient has a dominance of PGE-2, we would expect vasodilatation of major arteries with spasm of collateral circuits, which in turn can cause pain. Restoration of hormonal levels and balance between them can stabilize levels of prostaglandins.




Steroid hormones also influence the metabolism of calcium and magnesium. Estrogens regulate calcium metabolism, intestinal calcium absorption, and parathyroid gene expression and secretion, triggering fluctuations across the menstrual cycle. Alterations in calcium homeostasis have long been associated with many affective disturbances. Clinical trials in women with premenstrual syndrome have found that calcium supplementation may help alleviate most mood and somatic symptoms. Evidence to date indicates that women with symptoms of premenstrual syndrome have an underlying calcium abnormality.⁶³ A low brain magnesium level can be an expression of neuronal hyperexcitability of the visual pathways and be associated with a lowered threshold for migraine attacks.⁶⁴ Clinically, it is known that magnesium supplementation relieves premenstrual problems (for example, migraine, bloating, and edema) that occur late in the menstrual cycle, and that migraine, particularly in women, is associated with deficiencies in brain and serum magnesium levels. Testosterone was not shown to produce any significant alteration in magnesium levels, but estrogens and progesterone do.⁶⁵

In some but not all studies, patients with migraine showed a significant reduction of testosterone and a significantly increased cortisol concentration.⁶⁶⁻⁶⁹ We believe that a normal level of testosterone does not necessarily equate with an optimal level. Little attention has been paid thus far to androgens and their role, if any, in causing migraine.^{70,71} Our clinical experience strongly supports the notion that migraine can be managed only when levels of all the basic hormones—pregnenolone, DHEA, testosterone, estrogen, and progesterone—are optimal with the physiological cycle.⁷²

A New Hypothesis

The findings just described, in conjunction with our clinical observations, have led us to hypothesize that migraine is a specific consequence of the imbalance between neurohormonal and metabolic integrity. Based on our clinical experience, we have therefore suggested a unifying hypothesis, which we call the Neurohormonal and Metabolic Dysbalance Hypothesis of Migraine. Such a hypothesis not only brings together the many seemingly disconnected research findings for the first time, but also provides guidance for an effective treatment approach.



Migraine is not a single disorder, but a collection of disorders. According to our hypothesis, a migraine involves faulty hormonal feedback in the hypothalamic-pituitary-adrenal-gonadal axis. Contributing to this hormonal abnormality is an imbalance between two of the three arms of the autonomic nervous system (the sympathetic and parasympathetic nervous systems), which causes a decline in the brain's pain threshold. Because of disequilibrium between intra- and extracellular calcium and magnesium, the polarity of the cell membrane is changed, which affects the electrical stability of the cell membrane and sensitivity to neurohormonal impulses (steroid hormones, melatonin, and serotonin). Lastly, the intestinal flora is altered, which results in abnormal absorption.

The Migraine Solution

The old approach of focusing on the treatment of symptoms was replaced in our study with treating the cause of the disease. Herein we present our clinical experience with a series of particularly difficult-to-treat migraineurs in whom we simultaneously restored neurohormonal and metabolic integrity. We offered our treatment to 23 patients (21 women and 2 men) from May 2001 to May 2004. The patients ranged in age from 29 to 66, with a mean age of 46.7. The main characteristics and clinical summaries of these patients before treatment are reported in Table 1 on the following page.

Table 1. CLINICAL SUMMARY OF PATIENTS WITH MIGRAINE BEFORE TREATMENT

Patient	Sex	Age	Illness duration (years)	Migraine medicine	Concurrent symptoms or illness				Previously used hormone replacement therapy or oral contraceptive
					Fibromyalgia	Insomnia	Depression	Fatigue	
1	F	52	20	+	+	+	+	+	-
2	F	29	10	+	+	+	+	+	+
3	F	58	9	+	+	+	+	+	+
4	F	52	9	+	-	+	+	+	+
5	F	56	6	+	-	-	+	+	+
6	F	53	6	+	-	+	+	+	+
7	F	42	17	+	-	+	+	+	+
8	F	33	14	+	-	-	+	+	+

9	F	51	20	+	-	+	+	+	+
10	F	53	2	+	-	+	+	+	+
11	F	64	20	+	-	+	+	+	+
12	F	55	13	+	+	+	+	+	+
13	F	38	5	+	-	+	+	+	-
14	F	44	15	+	-	-	+	+	+
15	F	43	30	+	-	+	+	+	-
16	F	39	23	+	+	+	+	+	+
17	F	30	15	+	-	+	-	+	+
18	F	38	20	+	-	+	+	+	+
19	M	35	12	+	-	-	+	+	-
20	M	47	30	+	-	+	+	+	-
21	F	46	34	+	-	+	+	+	+
22	F	66	36	+	-	+	+	+	-
23	F	51	19	+	-	+	+	+	+

All of our patients had attempted—without success—to prevent or treat migraine with up to four standard drugs for periods ranging from 2 to 36 years (with a mean of 16.7 years). Nearly three of four patients (73.9%) had used hormone replacement therapy or oral contraceptives. Concurrent illnesses were noted as follows: fatigue in 100% of patients; depression in 95.7% of patients; insomnia in 82.6% of patients; and fibromyalgia in 21.7% of patients. This was consistent with other reports.⁷³⁻⁷⁶ Fibromyalgia, chronic fatigue, and primary headaches are common and debilitating disorders with complex interactions among each other.⁷⁷ We believe that this relationship is based on common abnormalities and that successful treatment is possible.

REPORT

An Innovative New Treatment for Migraine

By Dr. Sergey A. Dzigan

Following initial consultation, a baseline lipid profile was taken and levels of pregnenolone, dehydroepiandrosterone sulfate, progesterone, total estrogen, and total testosterone were determined through routine blood testing. Serial determinations were made thereafter during treatment.

All patients then underwent a comprehensive treatment program incorporating the following four components:

- hormonorestorative therapy with bio-identical hormones that included a combination of oral pregnenolone, DHEA, triestrogen, progesterone, and testosterone gels
- simultaneous correction of the imbalance between sympathetic and parasympathetic nervous systems and the ratio of calcium to magnesium
- "resetting" of the pineal gland through melatonin supplementation
- improvement of intestinal absorption through restoration of normal intestinal flora with the use of probiotics.

It must be stressed that these four components of the program cannot be separated; they are intertwined and work together. For example, by using estrogens and progesterone, we not only restored hormonal balance, but also helped restore a balance between the sympathetic and parasympathetic nervous systems. The same situation is associated with calcium and magnesium: by restoring metabolic integrity, we also restored balance between the sympathetic and parasympathetic nervous systems.

Hormonorestorative therapy includes a formula that is chemically identical to human hormones and is administered in physiological doses according to schedules intended to simulate natural human hormone production. Patients received treatment with oral pregnenolone, DHEA, and dermal applications of triestrogen (estriol 90%, estradiol 7%, estrone 3%), progesterone, and testosterone gels. All patients had steroid hormone deficiencies before beginning hormonorestorative therapy, with deficiencies in pregnenolone most prominent. Recommended doses to different patients varied significantly and were determined by serum hormone levels obtained during serial testing.



We did not use a standard dose, rigid protocol, or traditional design for this study. Doses were individually selected to produce youthful physiological serum levels. We administered hormones in doses sufficient to achieve circulating plasma levels observed in younger healthy adults between the ages of 20 and 30, who register the highest naturally occurring levels of all steroid hormones. These levels are at the high end of the normal range specified by the testing laboratory. Sixteen patients (69.6%) had been taking from one to three steroid hormones before beginning hormonorestorative therapy; none of the 16 reported obtaining any relief from these therapies, and all were still experiencing migraine before starting our program. All agents such as equine conjugated estrogens, medroxyprogesterone acetate, and methyl testosterone were switched to bio-identical hormones during treatment. Estrogens were always used in conjunction with progesterone.



Kava Leaf

Throughout the period of hormonorestitution, all of our patients were provided with an oral dose of 420 mg of magnesium citrate taken at bedtime. Patients were also given 3-6 mg of melatonin and 100-250 mg of kava root extract at bedtime. Kava has been shown to be effective as an alternative treatment in mild to moderate cases of anxiety. The pharmacological properties of kava are postulated to include blockade of voltage-gated sodium ion channels, enhanced ligand binding to gamma-aminobutyric acid (GABA) type-A receptors, diminished excitatory neurotransmitter release due to calcium ion channel blockade, reduced neuronal reuptake of noradrenaline (norepinephrine), reversible inhibition of monoamine oxidase B, and suppression of the synthesis of the eicosanoid thromboxane A(2), which antagonizes GABA(A) receptor function.⁷⁸ In this study, kava was used as part of the program without side effects. While kava remains on the market, you may wish to substitute L-theanine because of concerns about kava-

induced liver toxicity. For the restoration of healthy natural intestinal flora and improvement of absorption, 3.5 billion of the Lactobacillus group (L. rhamnosus A, L. rhamnosus B, L. acidophilus, L. casei, L. bulgaricus), 1 billion of the Bifidobacterium group (B. longum, B. breve), and 0.5 billion of Streptococcus thermophilus were introduced. Migraine is a recurrent clinical syndrome characterized by combinations of neurological, gastrointestinal, and autonomic manifestations.⁷⁹ We believe that restoration of natural intestinal flora is a very important element of our program.

Much to our satisfaction, all patients responded to migraine management with this multimodal treatment strategy. None of the patients suffered from migraine after initiating this program (a 100% success rate), indicating that migraine is not only treatable but also curable. Furthermore, the associated symptoms of fibromyalgia, insomnia, depression, and fatigue were resolved entirely.

During the follow-up period, no complications or side effects related to this regimen were cause for concern. Most important, all patients described a significant improvement in their quality of life.

REPORT


An Innovative New Treatment for Migraine

By Dr. Sergey A. Dzugan

Summary

Analysis of the medical literature and our own experience convince us that migraine is a complex disorder that comprises malfunctions in several systems: the neurohormonal system, which includes a feedback loop mechanism between the hypothalamus, pituitary gland, and glands that produce steroid hormones; the sympathetic-parasympathetic nervous systems; the calcium-magnesium ion system; the pineal gland; and the digestive system. All these systems and changes within them are closely interrelated, and each can be a trigger mechanism for migraine. Contradictory results with other migraine treatments—for example, using medications that modulate serotonin—offer additional evidence that the problem is not high or low sympathetic nervous system activity, but rather an imbalance between the sympathetic and parasympathetic nervous systems.

Following this logic, the basic method of migraine treatment must be directed toward restoring integrity between these different systems. In our hands, the simultaneous restoration of neurohormonal and metabolic integrity was an effective approach to the successful management of migraine.



References

1. Edmeads J. History of migraine treatment. *Can J Clin Pharmacol.* 1999;6 Suppl A:5A- 8A.
2. Mathew NT. Pathophysiology, epidemiology, and impact of migraine. *Clin Cornerstone.* 2001;4(3):1-17.
3. Gazerani P, Pourpak Z, Ahmadiani A, Hemmati A, Kazemnejad A. A correlation between migraine, histamine and immunoglobulin e. *Scand J Immunol.* 2003 Mar;57(3):286-90.
4. Lampl C, Buzath A, Baumhackl U, Klingler D. One-year prevalence of migraine in Austria: a nation-wide survey. *Cephalalgia.* 2003 May;23(4):280-6.
5. Granello F, Cavallini A, Sandrini G, Manzoni GC, Nappi G. Long-term outcome of migraine. *Cephalalgia.* 1998 Feb;18 Suppl 21:30-3.
6. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. *Neurology.* 1993 Jun;43 (6 Suppl 3):S6-10.
7. Rajda C, Tajti J, Komoroczy R, Seres E, Klivenyi P, Vecsei L. Amino acids in the saliva of patients with migraine. *Headache.* 1999 Oct;39(9):644-9.
8. Koehler PJ, Isler H. The early use of ergotamine in migraine. Edward Woakes' report of 1868, its theoretical and practical background and its international reception. *Cephalalgia.* 2002 Oct;22(8):686-91.
9. Allain H, Schuck S, Mauduit N, Saiag B, Pinel JF, Bentue-Ferrer D. The pathophysiology of migraine. *Pathol Biol (Paris).* 2000 Sep;48(7):613-8.
10. Prusinski A. Current views on pathophysiology of migraine: part I. Genetics of migraine. Genesis of the vascular theory. *Neurol Neurochir Pol.* 1995 Nov;29(6):845- 55.
11. Pichler M, Linzmayer L, Grunberger J, Wessely P. Stress management in migraine. *Wien Klin Wochenschr.* 1988 Jun 10;100(12):385-91.
12. Welch KM, Darnley D, Simkins RT. The role of estrogen in migraine: a review and hypothesis. *Cephalalgia.* 1984 Dec;4 (4):227- 36.
13. Guaschino S, Spinillo A, Sances G, Martignoni E. Menstrual migraine, old and new. *Clin Exp Obstet Gynecol.* 1985;12(3-

14. McCall RB, Huff R, Chio CL, et al. Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT_{1D} receptor agonist PNU- 142633. *Cephalalgia*. 2002 Dec;22(10):799- 806.
15. Horrobin DF. Hypothesis: prostaglandins and migraine. *Headache*. 1977 Jul;17(3):113-7.
16. Vardi Y, Rabey IM, Streifler M, Schwartz A, Lindner HR, Zor U. Migraine attacks. Alleviation by an inhibitor of prostaglandin synthesis and action. *Neurology*. 1976 May;26(5):447-50.
17. Hanington E. Migraine. A platelet hypothesis. *Biomedicine*. 1979 Jun;30(2):65-6.
18. Hanington E. Migraine: the platelet hypothesis after 10 years. *Biomed Pharmacother*. 1989;43(10):719-26.
19. Lance JW. Headache: classification, mechanism and principles of therapy, with particular reference to migraine. *Recent Prog Med*. 1989 Dec;80(12):673-80.
20. Burnstock G. Pathophysiology of migraine: a new hypothesis. *Lancet*. 1981 Jun 27;1(8235):1397-9.
21. Olsen TS, Friberg L, Lassen NA. Migraine aura—vascular or neuronal disease? *Ugeskr Laeger*. 1990 May 21;152(21):1507-9.
22. Skyhoj Olsen T. Migraine with and without aura: the same disease due to cerebral vasospasm of different intensity. A hypothesis based on CBF studies during migraine. *Headache*. 1990 Apr;30(5):269-72.
23. Feuerstein M, Bush C, Corbisiero R. Stress and chronic headache: a psychophysiological analysis of mechanisms. *J Psychosom Res*. 1982;26(2):167-82.
24. Glueck CJ, Bates SR. Migraine in children: association with primary and familial dyslipoproteinemias. *Pediatrics*. 1986 Mar;77(3):316-21.
25. Welch KM, D'Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. *Neurol Clin*. 1990 Nov;8(4):817- 28.
26. Schoenen J, Bottin D, Hardy F, Gerard P. Cephalic and extracephalic pressure pain thresholds in chronic tension-type headache. *Pain*. 1991 Nov;47(2):145-9.
27. Spector RH. Migraine. *Surv Ophthalmol*. 1984 Nov;29(3):193-207.
28. Gobel H, Heinze A, Stolze H, Heinze- Kuhn K, Lindner V. Open-labeled long- term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. *Cephalalgia*. 1999 Sep;19(7):676-83.
29. Rapoport AM. Frovatriptan: pharmacological differences and clinical results. *Curr Med Res Opin*. 2001;17 Suppl 1:s68-70.
30. Young WB, Hopkins MM, Shechter AL, Silberstein SD. Topiramate: a case series study in migraine prophylaxis. *Cephalalgia*. 2002 Oct;22(8):659-63.
31. Lake AE 3rd, Saper JR. Chronic headache: New advances in treatment strategies. *Neurology*. 2002 Sep 10;59(5 Suppl 2):S8-13.
32. Diamond S. Migraine headache. Its diagnosis and treatment. *Clin J Pain*. 1989;5(1):3-9.
33. Silberstein SD, Lipton RB. Overview of diagnosis and treatment of migraine. *Neurology*. 1994 Oct;44(10 Suppl 7):S6-16.
34. Baumel B. Migraine: a pharmacologic review with newer options and delivery modalities. *Neurology*. 1994 May;44(5 Suppl 3):S13-7.
35. Cady RK. Diagnosis and treatment of migraine. *Clin Cornerstone*. 1999;1(6):21- 32.
36. Young WB, Silberstein SD, Dayno JM. Migraine treatment. *Semin Neurol*. 1997;17(4):325-33.

37. Lance JW. Headache. *Ann Neurol*. 1981 Jul;10(1):1-10.
38. Ferrari MD. Biochemistry of migraine. *Pathol Biol (Paris)*. 1992 Apr;40(4):287-92.
39. Cassidy EM, Tomkins E, Dinan T, Hardiman O, O'Keane V. Central 5-HT receptor hypersensitivity in migraine with- out aura. *Cephalalgia*. 2003 Feb;23(1):29-34.
40. Selmaj K. Blood serotonin level in sciatica and the serotonin theory of migraine pathogenesis. *Neurol Neurochir Pol*. 1979 Mar;13(2):169-72.
41. Toglia JU. Melatonin: a significant contributor to the pathogenesis of migraine. *Med Hypotheses*. 2001 Oct;57(4):432-4.
42. Toglia JU. Is migraine due to a deficiency of pineal melatonin? *Ital J Neurol Sci*. 1986 Jun;7(3):319-23.
43. Claustrat B, Loisy C, Brun J, Beorchia S, Arnaud JL, Chazot G. Nocturnal plasma melatonin levels in migraine: a preliminary report. *Headache*. 1989 Apr;29(4):242-5.
44. Claustrat B, Brun J, Geoffriau M, Zaidan R, Mallo C, Chazot G. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. *Cephalalgia*. 1997 Jun;17(4):511-7.
45. Gagnier JJ. The therapeutic potential of melatonin in migraines and other headache types. *Altern Med Rev*. 2001 Aug;6(4):383- 9.
46. Lerchl A. Increased oxidation of pineal serotonin as a possible explanation for reduced melatonin synthesis in the aging Djungarian hamster (*Phodopus sungorus*). *Neurosci Lett*. 1994 Jul 18;176(1):25-8.
47. Rozenzweig R, Grad BR, Ochoa J. The role of melatonin and serotonin in aging. *Med Hypotheses*. 1987 Aug;23(4):337-52.
48. Maurizi CP. Disorder of the pineal gland associated with depression, peptic ulcers, and sexual dysfunction. *South Med J*. 1984 Dec;77(12):1516-8.
49. Gelmers HJ. Calcium-channel blockers in the treatment of migraine. *Am J Cardiol*. 1985 Jan 25;55(3):139B-43B.
50. Welch KM. Pathogenesis of migraine. *Semin Neurol*. 1997;17(4):335-41.
51. Silberstein SD. Sex hormones and headache. *Rev Neurol (Paris)*. 2000; 156 (Suppl 4):4S30- 41.
52. Silberstein SD. The role of sex hormones in headache. *Neurology*. 1992 Mar;42(3 Suppl 2):37-42.
53. Silberstein SD, Merriam GR. Estrogens, progestins, and headache. *Neurology*. 1991 Jun;41(6):786-93.
54. Murialdo G, Martignoni E, De Maria A, et al. Changes in the dopaminergic control of prolactin secretion and in ovarian steroids in migraine. *Cephalalgia*. 1986 Mar;6(1):43- 9.
55. Beckham JC, Krug LM, Penzien DB, et al. The relationship of ovarian steroids, headache activity and menstrual distress: a pilot study with female migraineurs. *Headache*. 1992 Jun;32(6):292-7.
56. Holdaway IM, Parr CE, France J. Treatment of a patient with severe menstrual migraine using the depot LHRH analogue Zoladex. *Aust N Z J Obstet Gynaecol*. 1991 May;31(2):164-5.
57. Sarrel PM. Ovarian hormones and the cir- culation. *Maturitas*. 1990 Sep;12(3):287-98.
58. Horowski R, Runge I. Possible role of gonadal hormones as triggering factors in migraine. *Funct Neurol*. 1986 Oct;1(4):405-14.
59. Sarrel PM. The differential effects of oestrogens and progestins on vascular tone. *Hum Reprod Update*. 1999 May;5(3):205-9.
60. Massiou H. Female hormones and migraine. *Pathol Biol (Paris)*. 2000 Sep;48(7):672-8.

61. Damasio H, Corbett JJ. Estrogens and migraine. *Ann Neurol*. 1981 Jan;9(1):92.
62. Magos AL, Zilkha KJ, Studd JW. Treatment of menstrual migraine by oestradiol implants. *J Neurol Neurosurg Psychiatry*. 1983 Nov;46(11):1044-6.
63. Thys-Jacobs S. Micronutrients and the pre-menstrual syndrome: the case for calcium. *J Am Coll Nutr*. 2000 Apr;19(2):220-7.
64. Aloisi P, Marrelli A, Porto C, Tozzi E, Cerone G. Visual evoked potentials and serum magnesium levels in juvenile migraine patients. *Headache*. 1997 Jun;37(6):383-5.
65. Li W, Zheng T, Altura BM, Altura BT. Sex steroid hormones exert biphasic effects on cytosolic magnesium ions in cerebral vascular smooth muscle cells: possible relationships to migraine frequency in premenstrual syndromes and stroke incidence. *Brain Res Bull*. 2001 Jan 1;54(1):83-9.
66. Facchinetti F, Nappi G, Cicoli C, et al. Reduced testosterone levels in cluster headache: a stress-related phenomenon? *Cephalalgia*. 1986 Mar;6(1):29-34.
67. Waldenlind E, Gustafsson SA. Prolactin in cluster headache: diurnal secretion, response to thyrotropin-releasing hormone, and relation to sex steroids and gonadotropins. *Cephalalgia*. 1987 Mar;7(1):43-54.
68. Romiti A, Martelletti P, Gallo MF, Giacobuzzo M. Low plasma testosterone levels in cluster headache. *Cephalalgia*. 1983 Mar;3(1):41-4.
69. Epstein MT, Hockaday JM, Hockaday TD. Migraine and reproductive hormones throughout the menstrual cycle. *Lancet*. 1975 Mar 8;1(7906):543-8.
70. Mattsson P. Serum levels of androgens and migraine in postmenopausal women. *Clin Sci (Lond)*. 2002 Nov;103(5):487-91.
71. Kudrow L. Changes of testosterone levels in the cluster headache syndrome. Preliminary study. *Minerva Med*. 1976 Jun 2;67(28):1850-3.
72. Dzigan SA, Smith RA. The simultaneous restoration of neurohormonal and metabolic integrity as a very promising method of migraine management. *Bull Urg Rec Med*. 2003;4(4):622-8.
73. Sheftell FD, Atlas SJ. Migraine and psychiatric comorbidity: from theory and hypotheses to clinical application. *Headache*. 2002 Oct;42(9):934-44.
74. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: investigating potential etiology and prognosis. *Neurology*. 2003 Apr 22;60(8):1308-12.
75. Bourgault P, Gratton F. Help-seeking behavior of women with migraines. *Rech Soins Infirm*. 2001 Jun;(65):83-92.
76. Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. *Adv Exp Med Biol*. 1996;398:373-9.
77. Peres MF. Fibromyalgia, fatigue, and headache disorders. *Curr Neurol Neurosci Rep*. 2003 Mar;3(2):97-103.
78. Singh YN, Singh NN. Therapeutic potential of kava in the treatment of anxiety disorders. *CNS Drugs*. 2002;16(11):731-43.
79. Diamond S, Wenzel R. Practical approaches to migraine management. *CNS Drugs*. 2002;16(6):385-403.

taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.